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Cost-effectiveness of different screening strategies
for abdominal aortic aneurysm
Anders Wanhainen, MD, PhD,a Jonas Lundkvist, MSc,b David Bergqvist, MD, PhD,a and
Martin Björck, MD, PhD,a Uppsala, Sweden
Objective:The primary objective of this study was to develop a simulation model to assess the cost-effectiveness of different
screening strategies for abdominal aortic aneurysms (AAAs) in men.
Methods: A systematic review of the literature was conducted for different screening strategies in terms of age (60, 65, or
70 years) and risk profiles (all men or specific high-risk groups) of the screened population, and rescreening after 5 or 10
years. These data were analyzed in a Markov simulation cohort model.
Results: The cost per life year gained for different screening strategies ranged from $8,309 to $14,084 and was estimated
at $10,474 when 65-year-old men were screened once. Screening 60-year-old men was equally cost-effective, with the
advantage of more life years gained. We demonstrated a trade-off between high prevalence of AAA and lower life
expectancy, eliminating the expected benefits of screening high-risk groups such as smokers ($10,695) or cardiovascular
patients ($10,392). Assuming general population utility resulted in a cost per quality-adjusted life year (QALY) gained
of $13,900, whereas a hypothetical 5% reduction in utility among men with a screening-detected AAA raised the cost per
QALY gained to $75,100.
Conclusion: This Markov model, which was based on a systematic review of the literature, supplied information on the
estimated cost-effectiveness of different screening strategies. Screening men for AAA may be cost-effective in the
long-term. Different screening strategies and quality-of-life effects related to screening for AAA need to be evaluated in
future clinical studies. ( J Vasc Surg 2005;41:741-51.)Abdominal aortic aneurysm (AAA) is a common disease,
particularly among elderly men, in whom the prevalence is 4%
to 7%.1-9 The rupture of an AAA is associated with high
mortality, causing about 1% of all fatalities in men 60 years
old.10 Most patients with a ruptured AAA die before they
come to surgery, and the overall mortality is about 80%
compared with a reportedmortality during elective surgery of
0% to 9%.1,4,10-25 Because of this difference in outcome, early
detection by screening has been advocated.26-30 However,
the benefits from early detection must be valued against the
added costs.
Studies of AAA screening have traditionally been based
on a one-time screening of men aged 65 years,1-7,31-37
since most ruptures occur in men above this age.26,38,39
Although the rupture incidence is lower in younger people,
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doi:10.1016/j.jvs.2005.01.055their life expectancy is longer, which means that the num-
ber of life years gained from one avoided death is greater. It
may therefore be cost-effective to screen men at younger
ages and possibly to rescreen those with an initial negative
screening. In addition to age and male sex, heredity, smok-
ing habits, and cardiovascular disease have also been iden-
tified as risk factors for AAA.40 Thus, a potential strategy
could be to screen risk populations with high prevalence of
the disease.
The key question for an evaluation of an AAA screening
program is, therefore, to identify an optimal strategy, that
is, to evaluate whom to screen, when to screen (at what
age), and how to design the screening program (a single
scan or rescreening).
The primary objective of this study was to develop a
simulation model to assess the cost-effectiveness of differ-
ent screening strategies for AAA. A secondary objective was
to identify critical areas where more information is needed
to reduce the uncertainty about the costs and consequences
of screening for AAA. Data for the study were obtained by
a systematic review of the literature.
METHODS
Two hypothetical groups are compared: one group
invited to ultrasound screening and another not invited.
The costs and effects are assessed by using a Markov cohort
simulation model.41 The model follows a cohort of patients
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The lifetime is divided into 1-year cycles.
An attendance rate is assumed, and those not attending
are assumed to be similar to the noninvited group regard-
ing risk of the different events. Patients in the model with
positive screening (a detected AAA) have yearly revisits to
follow the expansion of the aneurysm. They are offered
elective open surgery, if they are healthy enough, when the
AAA has grown to 55 mm, has expanded rapidly, or has
caused symptoms. Some patients with detected AAAs fulfill
the criteria for elective surgery at the time of screening and
are offered surgery as soon as possible. A proportion of the
AAAs in the nonscreened group will be detected opportu-
nistically. Each year, patients with AAAs are at risk of
rupture or death, either related to the AAA or because of
other causes.
False-negative AAA at the screening was not explicitly
included in themodel, because the prevalence of screening-
detected AAA was based on previous screening trials. False-
positive results may also occur, but their consequences are
Fig 1. Model structure. Each circle represents a Markov state.
The shaded circle labelled DEAD represents an absorbing state,
from where a person cannot leave. Arrows indicate allowed transi-
tions. The transition probabilities differ between the two groups
(invited to ultrasound screening or not invited). Those not attend-
ing are assumed to be similar to the noninvited group regarding
transition probabilities. AAA, Abdominal aortic aneurysm.reflected in the prevalence estimates and the risk of AAAexpansion, which also are based on previous screening
trials. The model is graphically depicted in Fig 1.
The base case analysis assumed a strategy where 65-
year-old Swedish men were invited once for screening.
Other screening strategies with different assumptions of the
age of the screened population, risk profiles, and introduc-
tion of rescreening were also analyzed.
The cost per life year gained (LYG) was the main
outcome measure and cost per quality-adjusted life years
(QALYs) was a secondary outcome measure. Costs and
effects were discounted at 3% annually.42 All costs are
presented in USD 2003 values (1 USD  7.2 SEK),
updated using the Swedish consumer price index.43
Literature review. A systematic review of the litera-
ture was conducted to estimate parameters in the model. In
a Medline search through January 2004, the keywords
abdominal aortic aneurysm and aortic aneurysm were used.
The following selection criteria were used:
1. Only population-based or multicenter studies were ac-
cepted. Single center studies were excluded because of
risk for differences in case mix, selection, and data
enhancement.44-46
2. The paper should be an original clinical research report.
Models, editorials, reviews, and letters were excluded.
3. The report should be published after 1990, because
inclusion criteria, performance, and outcome have
changed during the last decades.24,46-52 Older studies
may therefore not be representative of the situation
today. This criterion was relaxed for data on prevalence
in some of the risk groups studied because few such
studies were published after 1990.
4. The report should be written in English or Scandinavian
languages.
After the first selection step, 120 reports were read in
full by the main investigator (AW) and selected using the
following criteria:
1. The definition of an AAA should be given, 30 mm
being used in the present study.
2. Male sex-specific data should be available.
3. The age distribution of the patients should be described.
4. The follow-up period should be given.
5. The proportion of patients not participating, unfit for
surgery, or lost to follow-up should be given.
6. Only open repair was assessed in the model, because the
long-term results and associated costs of endovascular
aortic repair (EVAR) are unknown.
7. A distinction between surgery for ruptured and nonrup-
tured AAA should be possible.
Of the selected 120 reports, 65 fulfilled the criteria.
Two authors (AW and JL) extracted data from these finally
selected papers for the different parameters of the simula-
tion model. When there were difficulties in interpretation,
we reached a consensus. Pooled results were then used as
basis for each parameter estimate in the model.
Model probabilities. Table I displays the probabilities
in the model. The probability of a positive screening result
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five screening studies on 65-year-old men.3,5,6,8,9 Of these,
6.8% (0.09%) were assumed to be qualified and fit for
surgery directly.1,2,4,8,10,11,53-56 An attendance rate of 80%
was applied.1-7,10,57,58 We assumed in the base case that
patients with negative findings would not be followed-up.
Patients with an AAA would have a yearly risk of
undergoing open surgery for a nonruptured AAA. Data
from three randomized screening studies and one prospec-
tive, controlled screening study were used to estimate these
probabilities at 3.9% (0.09%) per year among those attend-
ing screening and 1.4% (0.05%) among those not attending
screening and in the noninvited group.1,4,10,55 It was as-
sumed that 13% (0.15%) of the AAAs in the nonscreened
patients would be opportunistically detected, a figure cal-
culated from the difference in rate of elective surgery in the
screened and nonscreened groups.1,4,10,55
Patients undergoing surgery for a nonruptured AAA
would have a mortality of 3.1% (0.42%) during surgery
according to mortality reported in the Swedish Vascular
Registry (Swedvasc) database.12 It was assumed to be the
same in the invited and noninvited groups. A mortality of
5.3% (0.04%), derived from 14 previous stud-
ies,1,11,12,15-25 was used in sensitivity analyses.
The rupture risk of anAAAwas estimated at 0.8% (0.04%)
per year among those attending screening and 1.9% (0.06%)
among those not attending screening and in the noninvited
group, based on data from three randomized screening stud-
ies and one prospective controlled screening study.1,4,10,55
From an analysis of 10 previous studies,1,4,10,11,13,14,23,24,37 it
was assumed that 65% (0.96%) of the patients with a ruptured
AAA would die before surgery and that an additional 14%
would die during surgery, corresponding to an operative
mortality of 40% (0.83%). Thus, the total mortality for AAA
rupture was 79%.
Because of comorbidity, patients with an AAA were
assumed to have an increased mortality unrelated to the
AAA compared with the general aged-matched population.
The increased mortality was estimated to be 2.05 times the
normal mortalities both before and after AAA surgery. The
estimate corresponds to a relative survival of 90% (0.56%)
after 5 years, derived from eight studies.23, 53, 59-64 Normal
death rates were based on population mortality statistics for
Swedish men.43
Additional screening strategies. The age of the
screened population varied between 60, 65, and 70 years,
with or without rescreening, after 5 or 10 years in people
with negative initial screening results. The screening of risk
groups of smokers, siblings of AAA patients, patients with
angina or claudication, and those with popliteal aneurysm
was analyzed.
The various strategies were assumed to differ from the
base case assumptions in the prevalence of AAA and the
mortality (Table II). The prevalence at rescreening was based
on estimated incidence rates39 and age-specific prevalence
data,7,65 adjusted for AAAs that would be removed from the
population by death or repair. It was assumed that all AAAs
identified at rescreening would be 55 mm.1,8,66-69Costs. The cost for inviting people to the screening
was incurred by all invited patients, whereas the cost of the
screening procedures was only incurred by those who at-
tended. The cost of invitation was estimated at $5.60 and
the cost of screening at $102.00 and $54.60 for persons
younger and older than 65 years. These figures were based
on the estimated costs in the Multicentre Aneurysm
Screening Study (MASS) study,70 adjusted for the relative
difference in price levels between Sweden and the United
Kingdom.71
The costs for the screening procedure in the present
study include additional costs due to the time lost during
the procedure and for travelling to the hospital. The cost
for lost time was estimated to be $55.20 for individuals
65 years and $7.90 for those 65 years on the assump-
tion that the examination would take about 2 hours. The
lost time was valued to the average hourly salary (including
social fees)71 for those 65 years and to the value of lost
leisure time, as estimated by the Swedish Road Authority,72
for individuals 65 years. The cost for travelling to the
screening was estimated to be $5.60, based on an assumed
cost for traveling within a city.
In analyses of risk groups with comorbid conditions, the
cost for inviting patients was excluded. We assumed that the
risk-group patients would be identified during their normal
visits to the hospital because of their comorbidities.
Patients with a detected AAAwere assumed to come for
yearly revisits to control the expansion of the aneurysm.
The cost of these revisits was estimated at $242.40.73 A
cost of $187.50 for a physician visit was added at the time of
detection for informing the patients about the AAA dis-
ease.73 The cost of elective AAA surgery was estimated at
$16,831 and the cost of surgery of a ruptured AAA was
estimated at $32,183.74
Using QALYs as outcome. To assess the cost per
QALY gained of AAA screening, data on quality of life in
terms of QALY for men with an AAA, either detected by
screening or not, and for men who have survived surgery for
AAA is required. No such data are available, therefore, we
based our assumptions on data for the general Swedish pop-
ulation. The quality of life for Swedishmen was measured as a
health utility value on a scale between 0 and 1 and was
estimated to be 0.88 for 60- to 69-year-olds, 0.77 for 70- to
79-year-olds, and 0.63 for 80-year-olds.75 In the base case,
individuals in all health states were assumed to have the same
QALY as the aged-match general population. In the sensitiv-
ity analysis, utility values for patients with a screening-detected
AAAs were hypothetically reduced by 5%, compared with the
aged-match general population, to test the possible effect of a
reduced quality of life due to worries. Also tested was an
additional analysis in which all those with anAAA, detected or
not, had a 5% hypothetical reduction in utility due to comor-
bidities. It should be noted that these 5% reductions were not
based on data from the literature.
Model validation and assessment of uncertainty.
The quality and validity of the analyses were assessed by
comparing the simulation results with results observed in
several clinical studies. Extensive sensitivity analyses were
JOURNAL OF VASCULAR SURGERY
May 2005744 Wanhainen et alperformed in which the different model parameters were
varied within the ranges found in previous studies (Table I)
to assess how they affected the results.
As a complementary analysis of the uncertainty, probabi-
listic sensitivity analysis was performed to examine the effect of
joint uncertainty of the variables. This method means that a
statistical distribution is assigned to the parameters in the
model instead of a point estimate only. The assumed distribu-
tions were based on information about the uncertainty re-
ported in the sources of the base case point estimates. Distri-
butions were not included for any of the costs, because no
information about the distribution of these estimates was
Table I. Summary of model probabilities
Assumption Probability
Prevalence 5.5%
Proportion qualified and fit for surgery
directly
6.8%
Attendance rate 80%
Proportion of opportunistically detected
AAA
13%
AAAs yearly risk for non-ruptured AAA
surgery, screened group
3.9%
AAAs yearly risk for non-ruptured AAA
surgery, non-screened group
1.4%
Mortality for non-rupture AAA surgery 3.1%
Ruptured AAA total mortality 79%
AAAs yearly risk of rupture, screened group 0.8%
AAAs yearly risk of rupture, non-screened
group
1.9%
AAA patient relative long term mortality 2.05
Cost of invitation $5.6
Cost of screening $54.6
Cost for travelling to the screening $5.6
Cost of follow-up $242.4
Cost of non-ruptured AAA surgery $16 831
Cost of surgery for ruptured AAA $32 183
Discounting 3% annually
AAA, Abdominal aortic aneurysm.
Table II. Risk group assumptions
Risk population
Init
AA
preval
65 year olds 5.5
Current smokers 9.5
Siblings 18.6
Angina or claudication 10%
PAA 50%
PAA, assuming higher mortality 50%
60 year olds 3.4
70 year olds 6.1
Rescreening of 65 year olds after 5 years 2.2
Rescreening of 60 year olds after 5 years 2.9
Rescreening of 60 year olds after 10 years 4.2
AAA, Abdominal aortic aneurysm; PAA, popliteal artery aneurysm.
*Relative risk in persons with AAA, compared to the general population.
†General population mortalities adjusted to correspond to 60 and 70 year o
‡The prevalence of new AAA detected at the rescreening.available.A large number of individually based (Monte Carlo)
simulations are then performedwhere a new set of parameters
for themodel are drawn from the assumeddistribution in each
of these simulations. This means that each of the individually
based simulations will use slightly different model parameters,
which also means that the simulations will result in different
cost-effectiveness ratios.
The distribution of the obtained cost-effectiveness ratios
gives information about the uncertainty in the mean cost-
effectiveness ratio. This uncertainty will be illustrated as an
acceptability curve that shows the proportion of estimates of
the cost-effectiveness ratios that falls below different values of
Range tested in
sensitivity analysis References
2% - 20% 3, 5, 6, 8, 9
— 1, 2, 4, 8, 10, 11, 53-56
50% - 90% 1-7, 10, 57, 58
— 1, 4, 10, 55
2.75% - 4.88% 1, 4, 10, 55
0.5% - 2.0% 1, 4, 10, 55
3.1% - 5.3% 1, 12, 15-25
71% - 84% 1, 4, 10, 11, 13, 14, 23, 24, 37
0.4% – 1.7% 1, 4, 10, 55
1.4% – 2.4% 1, 4, 10, 55
1.0 – 2.5 25, 43, 53, 59-64
— 65
–50% - 100% 43, 66, 67
— Assumption
— 68
$12,917 - $20,139 69
$21,111 - $42,361 69
0% - 5% 42
Mortality
risk* References
2.05 Base case
2.6 2, 70-76
2.05 77-84
2.5 2, 70, 85-88
2.05 89-91
2.5 89-91
2.05† 7, 39, 92
2.05† 7, 39, 92
2.05 7, 39, 92
2.05† 7, 39, 92
2.05† 7, 39, 92ial
A
ence
%
%
%
%
%
%‡
%‡
%‡
lds.willingness to pay for a life year.
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Base case results are presented in Table III. The mean
remaining life expectancies in the invited and noninvited
groups were estimated to be 16.0 and 15.9 years, and the
cost per LYG in the base case was estimated to be $10,474.
The estimatedmean remaining life expectancies were about
11.1 and 10.5 years in screened and nonscreened individ-
uals with an AAA. The incidences of surgery for nonrup-
tured AAAs and of AAA rupture were 1.58% and 0.49% in
the invited group and 0.63% and 1.04% in the noninvited
group. The AAA-related death incidence was 0.4% and
0.8% for the invited and noninvited group, which corre-
sponds to a 50% reduction. The analyses of alternative
screening strategies are presented in Table IV.
Assuming general population utility in all health states
resulted in a cost per QALY gained of $13,900 for the base
case strategy, which is slightly higher than the correspond-
ing cost per LYG. Assuming a 5% reduction in QALY for
worrying about the screening-detected AAA resulted in
cost per QALY gained of $75,100. Assuming a reduced
utility for all individuals with an AAA only marginally
affected the results and resulted in a cost per QALY gained
of $14,600.
Model validation and assessment of uncertainty. In
theMASS study, about 0.2% and 0.4% of the patients in the
screening and control groups had a ruptured AAA, and
about 1% and 0.3% underwent elective AAA surgery.1 The
corresponding 4-year estimates from our model for the
screening and control groups were 0.23% and 0.37% for a
ruptured AAA and 0.72% and 0.26% for elective AAA
surgery.
The MASS study found a difference of 0.14 deaths per
100 persons after 4 years and the Chichester study found a
difference in AAAmortality of 0.21 deaths per 100 persons
after 10 years.1,37 Our model estimated the mortality dif-
ferences to be 0.10 deaths per 100 persons after 4 years and
0.23 deaths per 100 persons after 10 years.
In a large population-based necropsy study, Bengtsson
et al92 found that 13% of all AAAs eventually rupture. The
corresponding proportion was 11% in our findings. The
yearly rates for surgery (3.9%) and rupture (0.8%) used in
our model correspond well to the findings in the UK Small
Table III. Base-case results of screening 65-year-old
men once, per person.
Cost* Noninvited
Invited for
screening Difference
Invitation 0.0 5.60 5.60
Screening 0.0 43.10 43.10
Follow-up 12.20 77.00 64.80
Elective surgery 92.00 232.40 140.40
Rupture surgery 92.60 48.20 –44.40
Total 196.80 406.30 209.50
Life years 12.132 12.152 0.020
*Cost in USDAneurysm Trial11 and in the Aneurysm Detection andManagement study,40 where 3.6% were operated on each
year and the yearly rupture rate was 0.7%, provided that
70% of all detected AAAs were 4.0 cm.1,5,8,40,58
One-way sensitivity analyses show that the probability
of fitting the criteria for elective surgery, the probability of
rupture in the screened and nonscreened groups, and long-
term survival were the most important parameters for the
cost-effectiveness (Table V). Fig 2 presents a cost-effective-
ness acceptability curve showing that screening was cost-
effective in 50% of the simulations if a life year was valued at
about $10,500 using the base case prevalence estimate. If a
life year was valued at $12,000, about 95% of the simula-
tions found the screening cost-effective.
DISCUSSION
The Markov model structure contained few health
states and the outcome showed good agreement with find-
ings in controlled empirical studies. The results were ro-
bust, as shown in various sensitivity analyses, and the ac-
ceptability curves were steep, indicating small variance in
the cost-effectiveness ratio. The analyses showed that the
cost-effectiveness was rather insensitive to variations in the
cost of screening and surgery, whereas variations of the risk
of rupture and long-term survival affected the cost-effec-
tiveness substantially.
The analyses also showed that the attendance rate had
very little effect on the cost-effectiveness ratio; however,
this may not be the case if the nonattenders are different
from the attenders. Some previous studies indicate that
those who do not attend screenings for AAA have an overall
mortality and risk of AAA similar to a control popula-
tion,1,56 whereas others indicate that nonattenders are less
healthy than attenders.76,77 A higher attendance rate means
that the average screening cost per person will be lower. On
the other hand, our analyses have indicated that the life
expectancy of the screened individuals is a key variable for
the cost-effectiveness ratio. Thus, if people who attend the
screening are healthier than those who do not attend, the
cost-effectiveness could be high despite a low attendance
rate.
We included a cost for inviting people to the screening,
but it should be noted that this cost would not be incurred
if the screening was part of clinical practice and was per-
formed at regular health care visits.
No clinical studies have assessed the cost-utility of
screening for AAA. Although no data on the utility in those
with an AAAwere available, some preliminary analyses with
QALYs as an outcome measure were performed to hypoth-
esize how this aspect could affect cost-effectiveness. The
cost per QALY gained was similar to the cost per LYG if
AAA patients were assumed to have the same utility as the
general population. However, if a reduced utility was as-
sumed for patients who have an AAA detected by screen-
ing, the cost-effectiveness was decreased. No reliable evi-
dence for such a reduction of utility from screening exists,
and this finding only indicates the great effect on the
cost-effectiveness of AAA screening of a possible quality-of-
life reduction caused by worries in patients who are diag-
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sive, however.1,78-85
The present study showed that the incremental cost per
Table IV. Results from analyses of other screening strateg
Screening strategy
Cost d
pe
65-year-olds with popliteal aneurysm, assuming
base-case population mortality
1
65-year-olds with popliteal aneurysm 1
65-year-old siblings
65-year-olds with angina or claudication
60-year-olds with angina or claudication
65-year-old smokers
60-year-old smokers
60-year-olds with re-screening after 5 years
60-year-olds with re-screening after 10 years
65-year-olds with re-screening after 5 years
65-year-olds (base case)
60-year-olds
70-year-olds
*Compared to no invitation to screening
Table V. Results from sensitivity analyses, per person
Parameter Assumption
C
Base case (screening 65-
year-old men once)
209.50
Initial AAA prevalence† 2%
4%
10%
20%
Elective surgery costs 12,917‡
20,139‡
Ruptured surgery costs 21,111‡
42,361‡
Cost of screening 100%
–50%
Elective surgery risk in
screened group
2.75% per year§
4.88% per year§
Elective surgery risk in
non-screened group
0.5% per year§
2.0% per year§
Ruptured risk in screened
group
0.4% per year§
1.7% per year§
Ruptured risk in non-
screened group
1.4% per year§
2.4% per year§
Relative mortality for
patients with AAA
1.0**
2.5**
Elective surgery mort 5.3%
Ruptured AAA total
mortality
71%§
84%§
Attendance rate 90%
50%
Discount rate 0% 231.9
Discount rate 5% 197.5
AAA, Abdominal aortic aneurysm.
*Compared to no invitation to screening
†Only AAA prevalence are adjusted, i.e. in this analysis the AAA patients ar
‡Difference compared to base case assumption based on the difference to th
§Assumptions based on the lowest and highest rates reported in previous st
**Compared to the general populationLYG for screening all 65-year-old men for AAA was lowerthan what is generally considered cost-effective,86-88 and
compares favorably with cited estimates of $26,000 to
$44,000 (in 2003 values) for the cost per LYG for screen-
men, per person
nce per
$)*
Difference in life
years per person*
Cost per life year
gained ($)*
00 0.182 8,309
30 0.156 9,148
70 0.068 8,761
20 0.031 10,392
10 0.029 9,841
30 0.029 10,695
80 0.026 10,203
20 0.025 11,648
60 0.023 12,168
60 0.023 11,946
50 0.020 10,474
40 0.018 11,100
40 0.014 14,084
ifference
$)*
Difference in life
years*
Cost per life year
gained ($)*
.020 10,474
.20 0.008 14,732
.70 0.015 11,387
.10 0.036 9,380
.60 0.073 8,711
.40 0.020 8,918
.50 0.020 11,973
.40 0.020 11,217
.70 0.020 9,732
.20 0.020 12,907
.20 0.020 9,258
.30 0.020 8,683
.10 0.020 11,824
.40 0.021 12,019
.80 0.020 9,320
.80 0.028 7,297
.80 0.006 41,766
.60 0.012 19,534
.00 0.030 6,558
7,3 0,032 7,413
0,8 0,017 11,664
.5 0.019 11,272
.6 0.018 11,079
.3 0.022 9,971
.0 0.023 10,444
.0 0.013 10,641
.028 8,374
.016 12,103
ssumed to be less healthy
mated costs in MASSies in
iffere
rson (
,511.
,431.
592.
325.
280.
308.
268.
293.
280.
278.
209.
197.
199.ost d
(
0
107
165
341
633
178
239
224
194
258
185
173
237
250
180
201
223
223
194
23
20
209
195
213
235
133
0
0
e not a
e esti
udiesing programs for cervical cancer, hypertension, and breast
curv
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threshold value per LYG or QALY gained,90 there are some
methods of estimating the willingness to pay for a LYG and
QALY. These different methods result in widely varying
results, however. A report by the World Health Organiza-
tion suggested a threshold of three times the gross domes-
tic product per disability-adjusted life years,90 which would
correspond to about $115,000. Based on the willingness to
pay for saving lives that was used for evaluating investments
in road safety in Sweden, a value per QALY of about
$89,000 (in 2003 value) has been calculated.91 A retro-
spective analysis of recommendations made by the National
Institute for Clinical Excellence in England and Wales has
indicated a threshold of $33,000 to $49,000 (in 2003
value).90
The cost per LYG was similar to that for screening risk
groups with a high prevalence of the disease. This finding
reflects that prevalence and life expectancy are two factors
influencing the cost-effectiveness in different directions.
The prevalence of AAA in smokers and in patients with
claudication or angina, for example, is higher than in the
general population,2,92-96 but the long-term mortality is
also higher.94,97 In younger individuals the situation is
opposite: the prevalence of AAA is lower and the life
expectancy is longer. The optimal age and risk group has to
be defined.
The assessment of different screening strategies indi-
cate that screening 60-year-olds, with rescreening after 5
years, results in the largest benefit in terms of LYG, with
low additional cost per LYG. No clinical studies exist to
support the concept of rescreening. However, follow-up
studies on normal or ectatic aortas are all based on screen-
ing older men and do not have a lifetime follow-
up.8,66,67,68 With an incidence peak at about 65 years,39
these reports may not be relevant when investigating 60-
Fig 2. Cost-effectiveness acceptabilityyear-old men.A single screening at 65 years may be safe,66,69 but a
single screening at 60 years may not, as this is in the middle
of the incidence peak. Furthermore, about 18% of all rup-
tured AAAs in men occur 65 years.12 Thus, by screening
60-year-old men, additional rupture could be prevented in
those with a longer life expectancy. This result stresses the
importance to assess different screening strategies in future
clinical studies and to define the optimal age group.
In the past decade, EVAR has emerged as an alternative
to open repair that may influence the cost-effectiveness of a
screening program for AAAs in several ways. In the short
term, aneurysm-related death rate appears to be signifi-
cantly lower for EVAR as a result of a lower initial periop-
erative mortality rate.98 EVAR may also be an option for
those considered unfit for open surgery. Because they rep-
resent most of those who eventually rupture, the introduc-
tion of EVAR in selected cases may further reduce the
AAA-related mortality and increase the efficiency of screen-
ing.
Although intensive care unit and total hospital stay is
significantly lower for EVAR, this saving is lost by the
additional cost for the EVAR device.99 Considering the
unknown cost of postoperative surveillance, the higher
secondary intervention rate, and the lack of long-term
outcome data on EVAR, it is impossible to currently eval-
uate the impact of EVAR on the cost-effectiveness.
We do not even know what proportion of the AAAs
detected by screening are possible to treat with EVAR,
although we have reason to speculate that it may be a very
large proportion. A higher cost and a better outcome after
EVAR may lead to a similar cost-effectiveness ratio as with
open repair. With more long-term data on the outcome
after EVAR, it will be possible in the future to estimate the
cost-effectiveness of an AAA screening program that uses
es (screening 65-year-old men once).EVAR in a proportion of the patients.
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screening for AAAs are heterogeneous concerning several
important criteria, making it difficult to compare the re-
sults. Most previous studies have found screening 65-year-
old men to be cost-effective.33,35,70 A model study by Boll
et al31 found a cost per LYG of $1,500, an evaluation based
on the MASS found a cost per LYG of $15 000,70 and a
United States study by Lee33 estimated the cost per LYG to
be $11,500.
The difference in cost-effectiveness seen between stud-
ies could be explained by differences in study or model
design and in differences in assumed probabilities. Factors
found important in this report, such as the opportunistic
detection of AAA and additional mortality in AAA patients,
were excluded in some studies.36 Other differences are the
discounting of costs and benefits, criteria for elective sur-
gery, and inclusion of ruptured AAAs occurring outside of
the hospital.4,32,100 The most important difference is the
age of the screened population, where most studies have
included a broad age-interval.
Limitations. The following methodologic limitations
may have influenced the results of this study:
● The natural course of AAAs is difficult to study and
information is scarce.
● Information obtained from studies of small AAAs or
patients unfit for surgery is incomplete because of
differences in the studied populations
● The estimated incidence of ruptured AAAs and surgery
for nonruptured AAAs was based on clinical studies
with limited follow-up.
● Most screening studies were based on older patients,
so data on AAAs in 60-year-olds are uncertain.
The assessment of uncertainty by probabilistic analysis
indicated a small variance in themean cost-effectiveness
ratio. However, these results should be interpreted
with some caution, because no information concerning
the distributions of the mortalities or cost assumptions
was included in the simulation model.
CONCLUSIONS
Screening for AAAmay be cost-effective in 65-year-old
men, whereas rescreening 60-year-old men could be
equally cost-effective with the advantage of more LYG.
However, more studies of different screening strategies are
necessary before any conclusion can be made about which
of the different screening strategies should be preferred.
Factors that need better characterization are the natural
course of AAAs detected by rescreening, the age-specific
natural course of the disease, and the quality-of-life effects
related to screening. The study also demonstrated a trade-
off between high AAA prevalence and lower life expectancy
in high-risk groups such as smokers and patients with
angina and claudication that eliminated most of the ex-
pected additional benefits of screening these groups selec-
tively.We thank Professor Bengt Jönsson and Professor Peter
Aspelin for their comments on the manuscript.
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The authors have developed a Markov decision analysis model
to examine the cost-effectiveness of different ultrasound scanning–
based screening strategies for abdominal aortic aneurysms (AAAs)
inmen. The various assumptions incorporated into themodel were
supported by an extensive systematic review of the literature and
were appropriately tested by using multiple sensitivity analyses.
Although the utility of the model and the validity of the results are
contingent on the accuracy of these assumptions, it seems that the
authors were both thoughtful and thorough in their approach. The
authors reported that the cost per life-year saved was $10,474 for a
65-year-old man screened once, with a range from $8309 to
$14,084 for the various other strategies, including patients with
popliteal artery aneurysms and those who had a sibling with an
AAA. Notably, screening resulted in only modest 0.1- and 0.6-year
increases in the mean life expectancies among all the patients
screened and the subset of those with an AAA, respectively. The
risk of aneurysm rupture and long-term survival had the most
dramatic effect on the cost-effectiveness of the screening strategies
in the sensitivity analyses. The results of the model were validated
by comparison with several large clinical trials that examined both
the screening and treatment of AAAs, although this validation was
not completely surprising because several of these definitive trials
were incorporated into the model assumptions. The cost per
quality-adjusted life-year saved for the aneurysm screening was well
below the frequently quoted $50,000/quality-adjusted life-year
threshold and was below the values reported for cervical cancer,
breast cancer, and hypertension screening, as reported by the
authors. Unfortunately, the authors’ conclusions that “screening
for AAA may be cost-effective in 65-year-old men, while screeningwith the advantage of more LYG (life years gained)” were not
definitive. The authors state that additional studies are necessary
before the preferred screening strategy can be identified. It is
important to note that all the AAA repairs in the model were
performed by using the open surgical technique. Although this
simplifies the analyses, it potentially limits the impact of the study,
given the expanding applications of the endovascular technique. It
is conceivable that the lower perioperative mortality rate associated
with the endovascular approach may offset the increased device-
and surveillance-related costs, as suggested by the authors.
The findings in this study further justify screening for AAA in
elderly men and demonstrate its cost-effectiveness. During the
review process of the authors’ manuscript, the United States Pre-
ventative Task Force issued a report recommending a single
screening ultrasound scan for AAA in men 65 to 75 years of age
who have a smoking history. The Preventative Task Force stated
that the literature did not substantiate AAA screening for women,
even among those with a family history of AAA, and stated that the
harms of screening outweighed the risks. Despite the strength of
the evidence supporting screening and the Preventative Task Force
recommendations, several challenges must be overcome before
screening becomes a routine clinical practice. We, as a collective
group of health-care providers that deal with patients with AAA,
must educate our primary care and cardiology colleagues. Further-
more, we must lobby our respective lawmakers in support of the
pending screening legislation initiated by the National Aneurysm
Alliance and the Society of Vascular Surgery. Finally, we must
initiate the appropriate clinical trials to resolve the outstanding
issues highlighted by the authors and the Preventative Task Force.
